1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AnaptysBio’s Imsidolimab Meets Yet Another Failure

 
• By Alaric DeArment

The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.

AnaptysBio is shifting its strategy after another trial of imsidolimab failed • Source: Shutterstock

The latest clinical trial failure of AnaptysBio, Inc.’s interleukin-36 receptor-targeting monoclonal antibody, imsidolimab, means the drug’s utility will stay mostly confined to generalized pustular psoriasis (GPP), where it will nevertheless face strong competition from Boehringer Ingelheim GmbH’s spesolimab. But it also gives the company the chance to shift its focus to other pipeline assets.

AnaptysBio said 31 August that the Phase II HARP trial of imsidolimab in hidradenitis suppurativa (HS) failed to meet its...

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D